Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Halozyme ( (HALO) ).
On March 17, 2025, Michael J. LaBarre, Senior Vice President and Chief Technical Officer of Halozyme Therapeutics, Inc., announced his retirement, effective immediately. The company acknowledged his significant contributions to their ENHANZE® drug delivery technology, marking a notable transition in their leadership team.
More about Halozyme
Halozyme Therapeutics, Inc. operates in the biotechnology industry, focusing on drug delivery technologies, notably their ENHANZE® technology.
YTD Price Performance: 33.93%
Average Trading Volume: 1,283,809
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $7.7B
For an in-depth examination of HALO stock, go to TipRanks’ Stock Analysis page.